In Brief: HumaScan Breast Alert
This article was originally published in The Gray Sheet
Executive Summary
HumaScan Breast Alert: Firm will commence sales through distributor Physician Sales & Service in December of its non-invasive differential temperature sensor (DTS) for use as an adjunctive tool for early detection of breast disease. Launch of the product has been delayed since July because of "refinements" made to HumaScan's manufacturing equipment ("The Gray Sheet" July 7, In Brief). HumaScan also is initiating a multi-center product performance study in women with biopsy-proven malignancies, data from which will support marketing and sales efforts, the company says...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.